MedCity News January 24, 2023
Medtech companies should have a team of FDA advisors at the ready to develop and implement pre- and post-market strategies, prevent and resolve pre- or post-market issues and guide lifecycle management
The ability to collect and leverage data — whether be it from the patient or from provider — is transforming the medtech industry. Consider companies that once largely developed hardware-based products. Now they provide a more comprehensive view of how patients behave.
All of this creates new compliance challenges. How should they address those?
Medtech companies should have a team of FDA advisors at the ready to develop and implement pre- and post-market strategies, prevent and resolve pre- or post-market issues and guide lifecycle management, with a keen understanding...
Today's Sponsors
Today's Sponsor